Autor:	Mel Spigelman, Richard J. O'Brien
Rok vydání:	2005
Předmět:	Pulmonary and Respiratory Medicine medicine.medical_specialty Tuberculosis business.industry Antitubercular Agents Rifamycins medicine.disease Clinical trial Immunology medicine Humans Intensive care medicine business
Zdroj:	Clinics in Chest Medicine. 26:327-340
ISSN:	0272-5231
Popis:	This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358b5048d86dc91879363f74a6e010bd https://doi.org/10.1016/j.ccm.2005.02.013 Zobrazit plný text záznamu